What did @lorrainekamesha actually say?
She reported 50 pounds of weight loss since August 2024 using compounded semaglutide through Mochi Health. Her claimed benefits include reduced facial inflammation, eliminated food cravings, and clearer skin. She also flagged real side effects: constipation, nausea on injection days, and appetite suppression so severe it caused a weight loss stall. That last point, that you have to eat to keep losing weight, is one of the more honest things you'll hear in a GLP-1 TikTok.
She credited hydration, protein intake, electrolytes, and Mochi's on-demand nutritionist access as her coping strategies. No specific doses were mentioned. No disease cure claims were made. She was transparent that side effects vary by person. As far as testimonial-style GLP-1 content goes, this one is more grounded than most.
Does the science back this up?
On weight loss, yes. On skin and inflammation claims, it is more complicated. The 50-pound figure is plausible but sits above average trial outcomes. The anti-inflammatory and acne benefits she described are biologically plausible but not yet proven by large clinical trials.
The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg produced an average 14.9% body weight reduction over 68 weeks in adults with obesity. Fifty pounds over roughly nine months is within range for someone with higher starting weight, but it is on the high end. GLP-1 receptors are present in immune cells, and some research (Drucker, 2018, Cell Metabolism) suggests GLP-1 agonists may reduce systemic inflammation via NF-kB pathway inhibition. A 2023 study (Bjornstad et al., NEJM) showed cardiovascular inflammation markers dropped with semaglutide use. However, the direct link to facial puffiness reduction is more likely explained by fat loss than by any discrete anti-inflammatory mechanism. The acne improvement she described is not documented in semaglutide trials. Dietary sugar reduction from appetite suppression could plausibly reduce acne, but that chain of causation has not been tested in this population.
What did they get wrong (or right)?
She got the core side effect profile right, and her tip about eating enough to avoid a weight loss stall is genuinely useful and often overlooked. Where the video gets shaky is the inflammation and acne framing, which implies semaglutide is treating those conditions directly.
Constipation is among the most consistently reported adverse effects in trial data. The STEP 1 trial reported gastrointestinal events in over 70% of semaglutide participants, with constipation specifically affecting around 24%. Her nausea management advice, protein, hydration, electrolytes, aligns with standard clinical guidance and is not harmful. The claim that her appetite went from "up here to all the way down here" accurately reflects how GLP-1 agonists slow gastric emptying and reduce hunger signaling in the hypothalamus. Her point that not eating causes a weight stall is correct: severe caloric restriction triggers adaptive thermogenesis and muscle catabolism, which can stall or reverse progress. This is worth saying plainly because a lot of GLP-1 content glosses over it entirely. The skin claims are where she should have been more careful. Saying your skin is "clear and glowing" after starting a medication implies causation that the evidence does not support.
What should you actually know?
Compounded semaglutide is not the same product as FDA-approved Wegovy or Ozempic. That distinction matters legally and clinically, and it should be stated clearly anywhere compounded versions are discussed.
The FDA placed compounded semaglutide on its shortage list, which allowed compounding pharmacies to produce it legally for a period. That status has shifted. As of early 2025, the FDA removed semaglutide from the drug shortage list, which has significant implications for the legal status of compounded versions going forward. Patients currently using compounded semaglutide through telehealth platforms should ask their provider directly about formulation, sourcing, and regulatory standing. Compounded drugs are not FDA-approved for safety or efficacy, and quality can vary between compounding pharmacies. This is not a reason to panic if you are already on it and it is working, but it is information you deserve to have. The weight loss results she described are real and consistent with what semaglutide does in clinical trials. The lifestyle scaffolding she described, nutrition support, hydration, protein focus, is also consistent with what produces better outcomes. A 2022 analysis (Wadden et al., Obesity) found that behavioral intervention combined with semaglutide produced meaningfully better outcomes than the drug alone.
Bottom line on this video
This is a paid partnership video with Mochi Health, and that context shapes everything about it. The personal results are plausible and some of the practical advice is genuinely good. But the inflammation and skin claims are not supported by clinical evidence for semaglutide specifically, and the video does not address the regulatory complexity around compounded versus brand-name formulations. Take the weight loss story at face value. Be more skeptical about anything beyond that.